Principal Investigator
|
Title
|
Organization
|
Status
|
ID
|
| Schwenkglenks, Matthias; Bucher, Heiner C. |
Health Technology Assessments for the Swiss Medical Board |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
2614006 |
| Schwenkglenks, Matthias, Hersberger, Kurt |
Übertragung niederländische PCG auf Schweizer Verhältnisse |
Departement Public Health / Pharmazeutische Medizin (Szucs),
Departement Pharmazeutische Wissenschaften / Pharmaceutical Care (Hersberger) |
Completed |
2748035 |
| Schwenkglenks, Matthias |
Kostenmodell Etanercept-Biosimilar |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4354690 |
| Schwenkglenks, Matthias |
Cost-effectiveness of hyperkalemia treatment |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
3529269 |
| Schwenkglenks, Matthias |
Cost-effectiveness of novel multiple sclerosis drug |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4491692 |
| Schwenkglenks, Matthias |
Cost-effectiveness of novel ophthalmology drugs |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4491703 |
| Schwenkglenks, Matthias |
Health economics of bronchitol dry powder |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
1594329 |
| Schwenkglenks, Matthias |
Cost-effectivness of chronic heart failure treatment |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
3008122 |
| Schwenkglenks, Matthias |
Regulierungsfolgenabschätzung zur Einführung eines Referenzpreissystems in der Schweiz |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4485812 |
| Schwenkglenks, Matthias |
Budget impact of GCSF biosimilars |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4529725 |
| Schwenkglenks, Matthias |
Impact and economics of inclisiran in Switzerland |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4602761 |
| Schwenkglenks, Matthias |
Impact of targeted therapy in patients with metastatic lung cancer |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4473765 |
| Schwenkglenks, Matthias |
Cost-effectiveness analysis of acute heart failure treatment |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
2250318 |
| Schwenkglenks, Matthias |
Cardiovascular surgery pathway model |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
1201882 |
| Schwenkglenks, Matthias |
Pill Protect: health-economic performance characteristics and implications for health care funding |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
3567316 |
| Schwenkglenks, Matthias |
Cost of HCV treatment in Switzerland |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
3511583 |
| Schwenkglenks, Matthias |
ENDOSCAPE, a clinically applicable non-viral gene delivery technology |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4491519 |
| Schwenkglenks, Matthias |
Health economic analysis of PENELOPE trial |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
2202031 |
| Schwenkglenks, Matthias |
Prospective observational study of outpatient osteoporosis treatment costs in Switzerland |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
1201998 |
| Schwenkglenks, Matthias |
Estimation of influenza hospitalisations from Medical Statistics of Hospitals |
Departement Public Health / Pharmazeutische Medizin (Szucs) |
Completed |
4605281 |
